Next-generation tissue engineering
Contact us
MorphoMed aims to become a leading development company for tissue engineering of ligaments and tendons based on its proprietary medical silk (MediSilk) technology, thus leading to tissue regeneration and recovery of the body’s own functional tissue. Our lead product RegACL, a regenerative anterior cruciate ligament from silk will enter into clinical trials end of 2018.
Our technology platform

“To morph” means “to transform in appearance, form or character”. In our case, MorphoMed’s novel MediSilk-based tissue engineering scaffolds are transformed into new body tissue. While the silk scaffold undergoes slow biological degradation, a new ligament or tendon is formed including aligned collagen fiber bundles, vascularization and anchoring bone tissue. 

In the future, the principle of tissue regeneration will become one of the most important sectors of modern medical device technology, since all implants, be they steel, polymers or other materials, have their limitations and will never fully mimic human tissue, especially not in the long term.
About us

MorphoMed is a medtech start-up company founded in Vienna in May 2017 and focuses on the development of new regenerative implants based on its proprietary medical silk (MediSilk) technology.

Our first lead product, a medical silk ACL (anterior cruciate ligament) transplant might help hundreds of thousands of patients after an ACL rupture to regenerate their ligaments and get back to normal life and including sports activities.
Share by: